• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

2024 AUA preview: Dr. Tawagi on top research in bladder cancer

Commentary
Video

Karine Tawagi, MD, highlights several studies in bladder cancer being presented at the 2024 American Urological Association Annual Meeting.

In this video, Karine Tawagi, MD, discusses several studies in bladder cancer being presented at the 2024 American Urological Association Annual Meeting in San Antonio, Texas. Tawagi is an assistant professor of medicine and a genitourinary medical oncologist at the University of Illinois in Chicago.

The following abstracts were previewed:

1. PD30-09 (Prasad et al): Response to primary chemoablation with UGN-102 in patients with new or recurrent LG IR NMIBC: Post-hoc analysis of the ATLAS trial

2. PD48-02 (Vilaseca et al): First safety and efficacy results of the TAR-210 erdafitnib intravesical delivery system in patients with non-muscle-invasive bladder cancer with select FGFR alterations

3. PD48-01 (Boorjian et al): Efficacy of nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: Final results from a phase 3 trial

4. Pivotal results from BOND-003: A phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (Tyson et al)

5. PD34-10 (Necchi et al): First results of Nure-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (PTS) with muscle-invasive bladder cancer (MIBC)

Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.